Since upregulated SMYD3 shapes the immunosuppressive microenvironment in ccRCC through the SREBP1‐CD47 axis, pharmacological inhibition of SMYD3 may have a synergistic effect with PD‐1 inhibitors to achieve increased tumor therapeutic efficacy. This evidence concerns the gene SMYD3 and neoplasm.